Document is current
Any future updates will be listed below
-
Authors
Reautschnig, Philipp https://orcid.org/0000-0003-4734-9317
Fruhner, Carolin
Wahn, Nicolai
Wiegand, Charlotte P.
Kragness, Sabrina
Yung, John F.
Hofacker, Daniel T. https://orcid.org/0000-0001-5880-0690
Fisk, Jenna
Eidelman, Michelle
Waffenschmidt, Nils
Feige, Maximilian
Pfeiffer, Laura S. https://orcid.org/0000-0002-2487-4138
Schulz, Annika E.
Füll, Yvonne https://orcid.org/0000-0003-2290-2366
Levanon, Erez Y. https://orcid.org/0000-0002-3641-4198
Mandel, Gail
Stafforst, Thorsten https://orcid.org/0000-0001-9359-3439
-
Funding
Funding for this research was provided by:
Volkswagen Foundation (96876)
International Rett Syndrome Foundation (3806)
Deutsche Forschungsgemeinschaft (STA 1053/11-1, STA 1053/10-1, IG-Reauts-2019-05)
U.S. Department of Health & Human Services | National Institutes of Health (NS110868)
Israel Science Foundation (2039/20, 2637/23)
- License Information
-
More Information
Article History
Received: 15 July 2023
Accepted: 17 May 2024
First Online: 12 July 2024
Competing interests
: T.S., G.M. N.W., C.P.W., L.S.P., A.E.S. and P.R. hold patents on site-directed RNA editing. T.S., C.P.W., A.E.S. and P.R. are inventors of a filed patent based on the work published here. T.S. is a cofounder and shareholder of AIRNA Bio. G.M. is a cofounder and shareholder of Vico Therapeutics. The other authors declare no conflicts of interest.
